Collaboration and License Agreement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 30, 2017	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Apr. 01, 2021	Jan. 01, 2021	Dec. 31, 2020	Apr. 01, 2020	Jan. 01, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized		$ 2,187	$ 567	$ 31,492	$ 1,155
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Revenue	$ 26,900
Novartis | Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized		1,400	$ 600	29,900	$ 1,200
Deferred revenue		800		800		$ 1,200	$ 29,400	$ 30,200	$ 200	$ 400
Novartis | Collaborative Arrangement | Reimbursable Research and Development Costs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable		$ 200		$ 200				$ 400